Blutersatz bei Herztransplantationen. [Blood replacement in heart transplantation]

Details

Serval ID
serval:BIB_AA6E8D3E84E4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Blutersatz bei Herztransplantationen. [Blood replacement in heart transplantation]
Journal
Beitrage zur InfusionsThérapie
Author(s)
von Segesser  L., Laske  A., Schmid  E. R., Turina  M.
ISSN
1011-6974
Publication state
Published
Issued date
1989
Volume
24
Pages
159-64
Notes
English Abstract
Journal Article
Abstract
Transfusion of blood and blood products in orthotopic heart transplantations were analysed in a series of 31 consecutive patients operated upon between September 1985 and December 1987. Mean age of the 29 men and 2 women was 41 +/- 12 years (range: 15-63). All patients had to be assigned to NYHA functional class IV before operation and their mean left ventricular fraction was 20%. The etiologies of cardiac disease leading to transplantation in this series were: cardiomyopathy in 19/31 patients (61%), ischemic heart disease in 7/31 (23%), valvular disease in 2/31 (6%), life threatening arrythmias in 2/31 (6%) and primary cardiac tumor in 1/31 (3%). Previous cardiac surgery had been performed in 6/31 patients (19%). Full anticoagulation with coumarines was observed in 24/31 patients (77%) at the time of surgery when mean PT was 33 +/- 12% and mean hematocrit was 40 +/- 4%. Mean blood products transfusion requirements in patients receiving an orthotopic heart transplant were 24.2 +/- 14.7 units (range 7-67 units) during the entire hospital stay. These figures are even higher if compiled in function of the number of donors of the transfused blood products: 29.2 +/- 22.4 (range 7-105). The following mean number of blood and blood components was perfused per patient: Red cells (hematocrit 50 +/- 10%) 4.4 +/- 3.9, concentrated red cells (hematocrit 70 + 10%) 5.9 +/- 4.3, fresh frozen plasma 7.4 +/- 3.3, platelets 3.9 +/- 4.1, and others (factor 8, 9 etc) 0.6 +/- 1.6. In-hospital mortality was 1/31 patients (3%) and actuarial survival is 27/31 (87%) at 33 months of follow-up (mean 17 +/- 7 months). However, 7/27 survivors (26%) had to be treated for cytomegaly acquired during or after the heart transplantation. Therefore transfusion of cytomegaly free blood products has to be recommended.
Keywords
Adult Blood Transfusion/*methods Erythrocyte Transfusion Female Follow-Up Studies Heart Diseases/*surgery Heart Transplantation/*methods Humans Intraoperative Complications/*therapy Male Plasma Postoperative Complications/*therapy
Pubmed
Web of science
Create date
14/02/2008 15:18
Last modification date
20/08/2019 16:14
Usage data